The Situation
Medtech company- The client sought to develop an innovative portfolio of drug delivery devices that met both HCP and patient needs and increased client’s competitive edge in the competitive diabetes and obesity GLP-1 markets
- Accordingly, the client wishes to understand the GLP-1 device journey (manufacturing, transportation, HCP prescribing, nursing, pharmacy) as well as patient/caregiver preferences on device attributes and optimal combinations of features to drive usage
Trinity’s Solution
- To develop a preliminary understanding of critical unmet needs and differences in device journey across and within markets, interviews with N=12 patient advocacy groups (PAGs), HCP KOLs, and industry experts were conducted
- Based on these initial interviews and Trinity expertise, target product profiles (TPPs) were further developed and refined through several workshopping sessions (R&D, clinical, marketing, regulatory)
- Conducted 60-minute interviews with HCPs and Patients (N=100), in the US and EU3, to refine understanding of HCP and patient needs across the GLP-1 device journey, gauging TPP reactions and device preferences
Project Outcomes
Trinity gauged the anticipated impact of various device features on adoption and continued use to inform device design tradeoff decisions and select a launch injector device for its GLP-1 asset.
- Helped the client understand current GLP-1 device experience & unmet needs (current & future) and the patient journey from a device/home use perspective
- Determined main trade-offs between attributes and minimal requirements for GLP-1 self-injection devices
- Assessed HCP & patient preferences for device feature functionality, and extent to which they would impact selection of a drug and drive continued use/adherence
If you have any questions, we’re here to answer them. We look forward to helping identify solutions for you.